Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
38
datasets available to search
ShareScore release 0.9.0
Dataset results
38 results for “MEDICATION OVERUSE”
Medication-overuse Headache: The Effect of a Patient Educational Programme as an add-on to Standard Treatment
ClinicalTrials.gov study NCT02768233. IPD Sharing: NO. Countries: 0. Publications: 1.
Medication Overuse Headache (MOH) and an Innovative Approach
ClinicalTrials.gov study NCT02435056. IPD Sharing: Not stated. Countries: 0. Publications: 8.
tDCS in Chronic Migraine With Medication Overuse (Edisom)
ClinicalTrials.gov study NCT04228809. IPD Sharing: NO. Countries: 0. Publications: 1.
Dataset related to article:MULTIMODAL DIGITAL HEALTH TREATMENTS FOR CHRONIC MIGRAINE ASSOCIATED WITH MEDICATION OVERUSE HEADACHE: A LITERATURE APPRAISAL AND RESULTS OF A SINGLE‑ARM OPEN TRIAL (THE BE‑HOME PROGRAM)
<p><strong><span>Variables related to baseline, months 3, 6 and 12 referred to headache frequency, medication intake, GSE, HIT-6, BDI-II, MSQ and PCS, of patients with CM and MOH who participated to the BE-HOME trial.</span></strong></p>
Efficacy and Central Mechanisms of Electroacupuncture for Medication Overuse Headache
ClinicalTrials.gov study NCT06802471. IPD Sharing: YES. Countries: 1. Publications: 0.
Longitudinal Study of the Patients With Medication-overuse Headache or Migraine That Completed Baseline MRI
ClinicalTrials.gov study NCT05528081. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
CBT in Patients With Medication Overuse Headache
ClinicalTrials.gov study NCT01754571. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pilot Study of DFN-11 Injection in Medication Overuse Headache
ClinicalTrials.gov study NCT02583425. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency
ClinicalTrials.gov study NCT04410536. IPD Sharing: NO. Countries: 1. Publications: 0.
Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment
ClinicalTrials.gov study NCT05608642. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Detoxification and Treatment of Subjects With Medication Overuse Headache
ClinicalTrials.gov study NCT00432549. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache
ClinicalTrials.gov study NCT01752439. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dataset related to article "WITHDRAWAL FAILURE IN PATIENTS WITH CHRONIC MIGRAINE AND MEDICATION OVERUSE HEADACHE"
<p>The file contains baseline and follow-up data (SPSS FILES .sav) referred to the MOH-COST study, used for a secondary analysis </p>
Anodal transcranial direct current stimulation in chronic migraine and medication overuse headache: A pilot double-blind randomized sham-controlled trial
<p>This dataset includes raw data from the article “Anodal transcranial direct current stimulation in chronic migraine and medication overuse headache: A pilot double-blind randomized sham-controlled trial”.</p> <p>In this study, we enrolled 20 patients with chronic migraine (CM) and medication overuse headache (MOH). They were hospitalized for a 7-day detoxification treatment and were randomly assigned to anodal tDCS or sham stimulation delivered over the primary motor cortex contralateral to the prevalent migraine pain side every day for 5 days. Clinical data were recorded at baseline (T0), after 1 month (T2) and 6 months (T3). EEG recording was performed at T0, at the end of the tDCS/Sham treatment, and at T2.</p> <p>At T2 and T3, we found a significant reduction in monthly migraine days (p = 0.001), which were more pronounced in the tDCS group when compared to the sham group (p = 0.016). At T2, we found a significant increase of alpha rhythm in occipital leads, which was significantly higher in tDCS group when compared to sham group. In conclusion, tDCS showed adjuvant effects to detoxification in the management of patients with CM and MOH. The EEG recording showed a significant potentiation of alpha rhythm, which may represent a correlate of the underlying changes in cortico-thalamic connections.</p>
Dataset related to Article "A SINGLE-GROUP STUDY ON THE EFFECT OF ONABOTULINUMTOXINA IN PATIENTS WITH CHRONIC MIGRAINE ASSOCIATED TO MEDICATION OVERUSE HEADACHE: PAIN CATASTROPHIZING PLAYS A ROLE"_ submitted
<p>THIS DATASET INCLUDES INFORMATION ON HEADACHE FREQUENCY, MEDICATION INTAKE, MIDAS SCORE, AVERAGE PAIN, HIT-6, ASC-12 AND PCS REFERRED TO PATIENTS RECEIVING ONABOTULINUMTOXINA AS PROPHYLAXIS FOR CM-MOH OVER 12 MONTHS.</p>
Data related to article EFFICACY OF MINDFULNESS ADDED TO TREATMENT AS USUAL IN PATIENTS WITH CHRONIC MIGRAINE AND MEDICATION OVERUSE HEADACHE: A PHASE-III SINGLE-BLIND RANDOMIZED-CONTROLLED TRIAL (THE MIND-CM STUDY) - submitted
<p>DATA ON PATIENTS INCLUDED IN THE MIND-CM STUDY. TWO ARMS (TAU AND TAU+MIND), AND FOUR EVALUATIONS: BASELINE, 3-MONTHS, 6-MONTHS AND 12-MONTS FOLLOW-UP.</p>
Theory of Mind assessed via real life materials in Chronic Migraine with Medication Overuse.
<p>Dataset refers to a study aimed to outline the Theory of Mind (ToM) functioning of patients with Chronic Migraine with Medication Overuse (CM+MO) compared to Episodic Migraine (EM) using the Movie for the Assessment of Social Cognition (MASC), a task consisting of the presentation of a 15-minute video clip of social interactions close to real life encounters in which participants are asked to identify and attribute mental states online. Seventy-two subjects were enrolled, of which 30 suffered from CM+MO and 42 from EM. All participants were assessed with a conventional ToM task, the Reading Mind in the Eyes test (RMET), and the MASC. We confirm impaired ToM performances in CM+MO with respect to EM when using the RMET. Interestingly, we also found that CM+MO when compared to EM were characterized by more marked deficits in the affective ToM dimension of the MASC with respect to the cognitive one and committed more hypomentalizing errors. This means that CM+MO patients may be more prone to under-interpret and misunderstand intended social interaction from another human being than the EM group. These findings have important theoretical and practical relevance in the field of CM+MO.</p>
Social cognition in Chronic Migraine with Medication Overuse: Do you mind what I think?
<p>This is the processed data for the manuscript “Bottiroli S, Rosi A, Sances G, Allena M, De Icco R, Lecce S, Vecchi T, Tassorelli C, Cavallini E. Social cognition in Chronic Migraine with Medication Overuse: Do you mind what I think?. To be submitted to JAMA Network Open”. </p> <p>Dataset refers to a study aimed to outline the socio-cognitive profile of patients with Chronic Migraine with Medication Overuse (CM+MO). Given the multidimensionality of the socio-cognitive construct, we considered: (1) socio-cognitive abilities, (2) socio-cognitive beliefs, (3) alexithymia and autism traits, and (4) social relationships. Two hundred and twelve subjects were enrolled, of which 71 suffered from CM+MO, 61 from episodic migraine (EM), and 80 were healthy controls (HC). All participants were assessed with a comprehensive socio-cognitive battery that included: (1) the Faux pas test (FP), the Strange Stories task (SS), the Reading Mind in the Eyes test (RMET), (2) the Tromso Social Intelligence Scale, (3) the Toronto Alexithymia Scale, (4) the Lubben Social Network Scale – Revised and the Friendship Scale. Data showed that CM+MO: (1) performed similar to EM but worse than HC in the FP and SS tests, while they were worse than the other two groups in the RMET; (2) were similar to EM and HC in terms of social intelligence; (3) had more alexithymic and autistic traits than EM and HC; and (4) reported higher levels of contact with their family members but felt little support from the people around them than HC. These results suggest that CM+MO patients are characterized by a profile of compromised socio-cognitive abilities that affects different dimensions.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.